Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study

被引：0
|
作者：
Yuan Zong
Jiajia Yuan
Zhi Peng
Ming Lu
Xicheng Wang
Lin Shen
Jun Zhou
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Gastrointestinal Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2021年 / 147卷
关键词：
Advanced pancreatic ductal adenocarcinoma; Chemotherapy; Nab-paclitaxel; S-1; Gemcitabine; Objective response rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1529 / 1536
页数：7
相关论文
共 50 条
  • [41] Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-na?ve advanced pancreatic ductal adenocarcinoma
    Zhou Zhu
    Hui Tang
    Jinrong Ying
    Yuejuan Cheng
    Xiang Wang
    Yingyi Wang
    Chunmei Bai
    Cancer Biology & Medicine, 2023, 20 (10) : 765 - 778
  • [42] A phase I study of gemcitabine/nab-paclitaxel/S-1 chemotherapy in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
    Chang, Chen
    Li, Xiaofen
    Cheng, Ke
    Cai, Zhaolun
    Xiong, Junjie
    Lv, Wanrui
    Li, Ruizhen
    Zhang, Pei
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16261 - E16261
  • [43] Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-na?ve advanced pancreatic ductal adenocarcinoma
    Zhou Zhu
    Hui Tang
    Jinrong Ying
    Yuejuan Cheng
    Xiang Wang
    Yingyi Wang
    Chunmei Bai
    Cancer Biology & Medicine, 2023, (10) : 765 - 778
  • [44] Efficacy and safety of gemcitabine plus S-1 vs. gemcitabine plus nab-paclitaxel in treatment-naïve advanced pancreatic ductal adenocarcinoma
    Zhu, Zhou
    Tang, Hui
    Ying, Jinrong
    Cheng, Yuejuan
    Wang, Xiang
    Wang, Yingyi
    Bai, Chunmei
    CANCER BIOLOGY & MEDICINE, 2023, 20 (10) : 765 - 778
  • [45] Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma
    Ielpo, B.
    Duran, H.
    Diaz, E.
    Fabra, I.
    Caruso, R.
    Fern, V.
    Malave, L.
    Hidalgo, M.
    Alvarez, R.
    Plaza, C.
    Quijano, Y.
    Vicente, E.
    EJSO, 2016, 42 (09): : 1394 - 1400
  • [46] Predictors of vulnerability to nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer
    Iede, Kiyotsugu
    Yamada, Terumasa
    Tominaga, Shusei
    ANNALS OF ONCOLOGY, 2023, 34 : S1453 - S1453
  • [47] First-line chemotherapies with FOLFIRINOX or gemcitabine plus nab-paclitaxel for unresectable pancreatic ductal adenocarcinoma in Japanese daily clinical practice
    Yano, M.
    Terashima, T.
    Yamashita, T.
    Miyazawa, M.
    Mizuno, H.
    Nomura, Y.
    Omura, H.
    Takata, Y.
    Ooishi, N.
    Shugo, H.
    Yamada, K.
    Takabatake, H.
    Takatori, H.
    Hodo, Y.
    Nishino, R.
    Hayashi, T.
    Mizukoshi, E.
    Kaneko, S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [48] A retrospective analysis of S-1 in patients with Gemcitabine plus nab-Paclitaxel refractory pancreatic cancer
    Tsumura, Hidetaka
    Sakai, Hideki
    Tokuyama, Nagahiro
    Kushida, Saeko
    Sakai, Aya
    Mimura, Takuya
    Sakamoto, Takeshi
    Yamamoto, Yoshinobu
    Miki, Ikuya
    Tsuda, Masahiro
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] The retrospective analysis of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Ueno, M.
    Kobayashi, S.
    Ohkawa, S.
    Tezuka, S.
    Moriya, S.
    Morimoto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 67 - 67
  • [50] Survival of patients with advanced pancreatic cancer is increased by nab-paclitaxel plus gemcitabine
    Nature Reviews Gastroenterology & Hepatology, 2013, 10 (12) : 695 - 695
12345